Cardiovascular Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments
- AMR-1067536
- January 2022
- Pharmaceuticals
- 125 Pages
This report is a comprehensive study that examines the Cardiovascular Drugs industry in depth. With reference to key regions and major nations, the study specifies the product type of Cardiovascular Drugs as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Cardiovascular Drugs market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Cardiovascular Drugs market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.
The top vendors and distributors operating in all of the major regions have also been highlighted in the Cardiovascular Drugs market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
Cardiovascular Drugs Market Strategic Analysis
The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Cardiovascular Drugs market study. The market dynamics and factors such as the threat of a Cardiovascular Drugs substitute, the threat of new entrants into the Cardiovascular Drugs market, buyer bargaining power, supplier bargaining power to Cardiovascular Drugs providing companies, and internal rivalry among Cardiovascular Drugs providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.
This analysis assists report users in evaluating the Cardiovascular Drugs market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Cardiovascular Drugs industry.
Cardiovascular Drugs Market Key Trends Analysis
The important factors influencing the growth of the Cardiovascular Drugs market have been examined in this report. The driving factors that are boosting demand for Cardiovascular Drugss and the restraining factors that are slowing growth of the Cardiovascular Drugs industry are addressed in depth, as well as their implications for the worldwide Cardiovascular Drugs market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.
Cardiovascular Drugs Market Key Segment Analysis
By segmenting the market by product type, application, and geography, the study provides a clear picture of the Cardiovascular Drugs industry. On the basis of current and future trends, all segments of the Cardiovascular Drugs industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.
The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.
The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
Cardiovascular Drugs Market Regional Trends and Market Player’s Analysis
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Cardiovascular Drugs market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Cardiovascular Drugs market throughout the projected period.
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Cardiovascular Drugs market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Cardiovascular Drugs market. All important stakeholders in the Cardiovascular Drugs value chain and technological ecosystem are expected to benefit from the insights offered in the Cardiovascular Drugs market research study.
In order to provide a broader understanding of the top competitors in the Cardiovascular Drugs market, the research includes a company market share analysis. Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca plc, Amgen Inc, Aurobindo Pharma Ltd, Bayer AG, Baxter International Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Ltd, Daiichi Sankyo Company Limited, Eli Lilly and Company, F.Hoffman-La Roche Ltd, Gilead Science, Inc, GlaxoSmithKline plc, Johnson & Johnson, Lupin Ltd, Merck & Co Inc, Medicure Inc, Novartis AG, Otsuka Pharmaceutical, Pfizer Inc are among the major participants in the global Cardiovascular Drugs industry.
Scope of the report
| Report Parameters | Details of Parameter |
|---|---|
| Market Size | xx Million |
| Based Year | 2021 |
| Forecast Period Covered | 2021-2028 |
| Units for value | Revenue in USD million and CAGR from 2021 to 2028 |
| Covered Segments | Component, Types, Applications, End-Users, and more. |
| Region Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca plc, Amgen Inc, Aurobindo Pharma Ltd, Bayer AG, Baxter International Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Ltd, Daiichi Sankyo Company Limited, Eli Lilly and Company, F.Hoffman-La Roche Ltd, Gilead Science, Inc, GlaxoSmithKline plc, Johnson & Johnson, Lupin Ltd, Merck & Co Inc, Medicure Inc, Novartis AG, Otsuka Pharmaceutical, Pfizer Inc |
Major Highlights of the Cardiovascular Drugs Market report study:
- An in-depth examination of the global Cardiovascular Drugs industry will be published soon.
- The study examines the global Cardiovascular Drugs market and offers major actionable information to its players.
- The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
- The report study is expected to aid the industry's key decision-makers in their decision-making process.
- Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
- The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Cardiovascular Drugs industry.
- The Market Ecosystem and Adoption in Different Markets
- The global Cardiovascular Drugs market is being shaped by several major trends.
- The size of the Cardiovascular Drugs market in terms of revenue has been measured in the past and will be measured in the future in USD million.
- Consumer preference patterns and recent industrial developments
- The worldwide Cardiovascular Drugs market's competitive landscape and player positioning analysis
- Major players' key goods and solutions, as well as their business strategies
- Recommendations for new market entrants as well as existing market participants.
- The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
- Operating players in the market encounter a number of significant hurdles.
- An examination of the major risks involved in market operations
The report segment of the global Cardiovascular Drugs market as follows:
Global Cardiovascular Drugs Market: By Product Type
- Type I
- Type II
- Type III
Global Cardiovascular Drugs Market: By Application
- Application I
- Application II
- Application III
Global Cardiovascular Drugs Market: By Region
- North America
- U.S.
- Canada
- Rest of North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
The report study is drafted to provide actionable insights to the following mentioned audience:
- Institutes of research and consulting firms
- Companies are attempting to get into the Cardiovascular Drugs market.
- Universities and students
- Other companies in the Cardiovascular Drugs market include solution providers, product producers, service providers, and others.
- Private companies and government agencies that are linked
- Individuals interested in learning more about the Cardiovascular Drugs market
Manufacturers and Segments
- Abbott Laboratories
- Astellas Pharma, Inc.
- AstraZeneca plc
- Amgen Inc
- Aurobindo Pharma Ltd
- Bayer AG
- Baxter International Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- F.Hoffman-La Roche Ltd
- Gilead Science, Inc
- GlaxoSmithKline plc
- Johnson & Johnson
- Lupin Ltd
- Merck & Co Inc
- Medicure Inc
- Novartis AG
- Otsuka Pharmaceutical
- Pfizer Inc
- Type I
- Type II
- Type III
- Application I
- Application II
- Application III
Have query on this report?
Make an Enquiry
1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
2. Executive Summarysegment Form
2.1. Global Cardiovascular Drugs Market Snapshot
2.1.1. Global Cardiovascular Drugs Market By Type I,2019
2.1.1.1.
2.1.1.2.Type I I
2.1.1.3.Type I II
2.1.2. Global Cardiovascular Drugs Market By Application I,2019
2.1.2.1.
2.1.2.2.Application I I
2.1.2.3.Application I II
2.1.3. Global Cardiovascular Drugs Market By End-use,2019
2.1.4. Global Cardiovascular Drugs Market By Geography,2019
3. Global Cardiovascular Drugs Market Dynamics
3.1. Market Overview
3.2. Market Inclination Insights Analysis
3.3. Drivers
3.4. Challenges
3.5. Future Prospects
3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)
4. Global Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
4.1. Overview
4.1.1. Market Share Analysis By Type I, 2019 vs.2028
4.1.2. Attractive Investment Proposition By Type I, 2020
4.2. Global Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
5. Global Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
5.1. Overview
5.1.1. Market Share Analysis By Application I, 2019 vs.2028
5.1.2. Attractive Investment Proposition By Application I, 2020
5.2. Global Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
6. Global Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
6.1. Overview
6.1.1. Market Share Analysis By End-use, 2019 vs.2028
6.1.2. Attractive Investment Proposition By End-use, 2020
6.2. Global Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7. Global Cardiovascular Drugs Market Size (US$), By Geography, 2018 – 2028
7.1. Overview
7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
7.1.2. Attractive Investment Proposition by Geography, 2020
7.2. North America Cardiovascular Drugs Market Analysis, 2018 – 2028
7.2.1. North America Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.2. North America Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.2.3. North America Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.2.4. North America Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.3. Europe Cardiovascular Drugs Market Analysis, 2018 – 2028
7.3.1. Europe Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.3.1.1. U.K.
7.3.1.2. Germany
7.3.1.3. France
7.3.1.4. Rest of Europe
7.3.2. Europe Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.3.3. Europe Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.3.4. Europe Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.4. Asia Pacific Cardiovascular Drugs Market Analysis , 2018 – 2028
7.4.1. Asia Pacific Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.4.1.1. China
7.4.1.2. Japan
7.4.1.3. India
7.4.1.4. Rest of Asia Pacific
7.4.2. Asia Pacific Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.4.3. Asia Pacific Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.4.4. Asia Pacific Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.5. Latin America Cardiovascular Drugs Market Analysis, 2018 – 2028
7.5.1. Latin America Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.5.3. Latin America Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.5.4. Latin America Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.6. Middle East & Africa (MEA) Cardiovascular Drugs Market Analysis, 2018 – 2028
7.6.1. MEA Cardiovascular Drugs Market Size (US$), By Region, 2018 – 2028
7.6.1.1. GCC Countries
7.6.1.2. South Africa
7.6.1.3. Rest of MEA
7.6.2. MEA Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.6.3. MEA Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.6.4. MEA Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
8. Company Profiles
8.1. Competitive Analysis
8.2. Market Positioning of Key Vendors
8.3. Key Strategies adopted by the Leading Players
8.4. Key Cardiovascular Drugs Providers
8.4.1 Abbott Laboratories
8.4.1.1 Business Description
8.4.1.2 Abbott Laboratories Geographic Operations
8.4.1.3 Abbott Laboratories Financial Information
8.4.1.4 Abbott Laboratories Product Positions/Portfolio
8.4.1.5 Abbott Laboratories Key Developments
8.4.2 Astellas Pharma, Inc.
8.4.2.1 Business Description
8.4.2.2 Astellas Pharma, Inc. Geographic Operations
8.4.2.3 Astellas Pharma, Inc. Financial Information
8.4.2.4 Astellas Pharma, Inc. Product Positions/Portfolio
8.4.2.5 Astellas Pharma, Inc. Key Developments
8.4.3 AstraZeneca plc
8.4.3.1 Business Description
8.4.3.2 AstraZeneca plc Geographic Operations
8.4.3.3 AstraZeneca plc Financial Information
8.4.3.4 AstraZeneca plc Product Positions/Portfolio
8.4.3.5 AstraZeneca plc Key Developments
8.4.4 Amgen Inc
8.4.4.1 Business Description
8.4.4.2 Amgen Inc Geographic Operations
8.4.4.3 Amgen Inc Financial Information
8.4.4.4 Amgen Inc Product Positions/Portfolio
8.4.4.5 Amgen Inc Key Developments
8.4.5 Aurobindo Pharma Ltd
8.4.5.1 Business Description
8.4.5.2 Aurobindo Pharma Ltd Geographic Operations
8.4.5.3 Aurobindo Pharma Ltd Financial Information
8.4.5.4 Aurobindo Pharma Ltd Product Positions/Portfolio
8.4.5.5 Aurobindo Pharma Ltd Key Developments
8.4.6 Bayer AG
8.4.6.1 Business Description
8.4.6.2 Bayer AG Geographic Operations
8.4.6.3 Bayer AG Financial Information
8.4.6.4 Bayer AG Product Positions/Portfolio
8.4.6.5 Bayer AG Key Developments
8.4.7 Baxter International Inc
8.4.7.1 Business Description
8.4.7.2 Baxter International Inc Geographic Operations
8.4.7.3 Baxter International Inc Financial Information
8.4.7.4 Baxter International Inc Product Positions/Portfolio
8.4.7.5 Baxter International Inc Key Developments
8.4.8 Boehringer Ingelheim GmbH
8.4.8.1 Business Description
8.4.8.2 Boehringer Ingelheim GmbH Geographic Operations
8.4.8.3 Boehringer Ingelheim GmbH Financial Information
8.4.8.4 Boehringer Ingelheim GmbH Product Positions/Portfolio
8.4.8.5 Boehringer Ingelheim GmbH Key Developments
8.4.9 Bristol-Myers Squibb Company
8.4.9.1 Business Description
8.4.9.2 Bristol-Myers Squibb Company Geographic Operations
8.4.9.3 Bristol-Myers Squibb Company Financial Information
8.4.9.4 Bristol-Myers Squibb Company Product Positions/Portfolio
8.4.9.5 Bristol-Myers Squibb Company Key Developments
8.4.10 Cipla Ltd
8.4.10.1 Business Description
8.4.10.2 Cipla Ltd Geographic Operations
8.4.10.3 Cipla Ltd Financial Information
8.4.10.4 Cipla Ltd Product Positions/Portfolio
8.4.10.5 Cipla Ltd Key Developments
8.4.11 Daiichi Sankyo Company Limited
8.4.11.1 Business Description
8.4.11.2 Daiichi Sankyo Company Limited Geographic Operations
8.4.11.3 Daiichi Sankyo Company Limited Financial Information
8.4.11.4 Daiichi Sankyo Company Limited Product Positions/Portfolio
8.4.11.5 Daiichi Sankyo Company Limited Key Developments
8.4.12 Eli Lilly and Company
8.4.12.1 Business Description
8.4.12.2 Eli Lilly and Company Geographic Operations
8.4.12.3 Eli Lilly and Company Financial Information
8.4.12.4 Eli Lilly and Company Product Positions/Portfolio
8.4.12.5 Eli Lilly and Company Key Developments
8.4.13 F.Hoffman-La Roche Ltd
8.4.13.1 Business Description
8.4.13.2 F.Hoffman-La Roche Ltd Geographic Operations
8.4.13.3 F.Hoffman-La Roche Ltd Financial Information
8.4.13.4 F.Hoffman-La Roche Ltd Product Positions/Portfolio
8.4.13.5 F.Hoffman-La Roche Ltd Key Developments
8.4.14 Gilead Science, Inc
8.4.14.1 Business Description
8.4.14.2 Gilead Science, Inc Geographic Operations
8.4.14.3 Gilead Science, Inc Financial Information
8.4.14.4 Gilead Science, Inc Product Positions/Portfolio
8.4.14.5 Gilead Science, Inc Key Developments
8.4.15 GlaxoSmithKline plc
8.4.15.1 Business Description
8.4.15.2 GlaxoSmithKline plc Geographic Operations
8.4.15.3 GlaxoSmithKline plc Financial Information
8.4.15.4 GlaxoSmithKline plc Product Positions/Portfolio
8.4.15.5 GlaxoSmithKline plc Key Developments
8.4.16 Johnson & Johnson
8.4.16.1 Business Description
8.4.16.2 Johnson & Johnson Geographic Operations
8.4.16.3 Johnson & Johnson Financial Information
8.4.16.4 Johnson & Johnson Product Positions/Portfolio
8.4.16.5 Johnson & Johnson Key Developments
8.4.17 Lupin Ltd
8.4.17.1 Business Description
8.4.17.2 Lupin Ltd Geographic Operations
8.4.17.3 Lupin Ltd Financial Information
8.4.17.4 Lupin Ltd Product Positions/Portfolio
8.4.17.5 Lupin Ltd Key Developments
8.4.18 Merck & Co Inc
8.4.18.1 Business Description
8.4.18.2 Merck & Co Inc Geographic Operations
8.4.18.3 Merck & Co Inc Financial Information
8.4.18.4 Merck & Co Inc Product Positions/Portfolio
8.4.18.5 Merck & Co Inc Key Developments
8.4.19 Medicure Inc
8.4.19.1 Business Description
8.4.19.2 Medicure Inc Geographic Operations
8.4.19.3 Medicure Inc Financial Information
8.4.19.4 Medicure Inc Product Positions/Portfolio
8.4.19.5 Medicure Inc Key Developments
8.4.20 Novartis AG
8.4.20.1 Business Description
8.4.20.2 Novartis AG Geographic Operations
8.4.20.3 Novartis AG Financial Information
8.4.20.4 Novartis AG Product Positions/Portfolio
8.4.20.5 Novartis AG Key Developments
8.4.21 Otsuka Pharmaceutical
8.4.21.1 Business Description
8.4.21.2 Otsuka Pharmaceutical Geographic Operations
8.4.21.3 Otsuka Pharmaceutical Financial Information
8.4.21.4 Otsuka Pharmaceutical Product Positions/Portfolio
8.4.21.5 Otsuka Pharmaceutical Key Developments
8.4.22 Pfizer Inc
8.4.22.1 Business Description
8.4.22.2 Pfizer Inc Geographic Operations
8.4.22.3 Pfizer Inc Financial Information
8.4.22.4 Pfizer Inc Product Positions/Portfolio
8.4.22.5 Pfizer Inc Key Developments
LIST OF TABLES
TABLE 1 Market Snapshot: Global Cardiovascular Drugs Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 North America Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 5 North America Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 6 North America Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 7 Europe Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 8 Europe Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 9 Europe Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 10 Asia Pacific Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 11 Asia Pacific Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 12 Asia Pacific Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 13 Latin America Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 14 Latin America Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 15 Latin America Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 17 MEA Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 18 MEA Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
LIST OF FIGURES
FIG. 1 Global Cardiovascular Drugs: Market Segmentation
FIG. 2 Global Cardiovascular Drugs Market: Research Methodology
FIG. 3 Top-Down and Bottom-up Approach
FIG. 4 Global Cardiovascular Drugs Market, By Type I, 2019 (US$ Mn)
FIG. 5 Global Cardiovascular Drugs Market, By Application I, 2019 (US$ Mn)
FIG. 6 Global Cardiovascular Drugs Market, By End-use, 2019 (US$ Mn)
FIG. 7 Global Cardiovascular Drugs Market, By Geography, 2019 (US$ Mn)
FIG. 8 Global Cardiovascular Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition
FIG. 10 Market Positioning of Key Cardiovascular Drugs Providers, 2019
FIG. 11 Global Cardiovascular Drugs Market Revenue Contribution, By Type I, 2019 & 2028 (Value %)
FIG. 12 Global Cardiovascular Drugs Market Revenue Contribution, By Application I, 2019 & 2028 (Value %)
FIG. 13 Global Cardiovascular Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %)
FIG. 14 North America Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 15 Europe Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 16 Asia Pacific Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 17 Latin America Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
Key Takeaways:
1. Market value and estimate of the Cardiovascular Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
2. Executive Summarysegment Form
2.1. Global Cardiovascular Drugs Market Snapshot
2.1.1. Global Cardiovascular Drugs Market By Type I,2019
2.1.1.1.
2.1.1.2.Type I I
2.1.1.3.Type I II
2.1.2. Global Cardiovascular Drugs Market By Application I,2019
2.1.2.1.
2.1.2.2.Application I I
2.1.2.3.Application I II
2.1.3. Global Cardiovascular Drugs Market By End-use,2019
2.1.4. Global Cardiovascular Drugs Market By Geography,2019
3. Global Cardiovascular Drugs Market Dynamics
3.1. Market Overview
3.2. Market Inclination Insights Analysis
3.3. Drivers
3.4. Challenges
3.5. Future Prospects
3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)
4. Global Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
4.1. Overview
4.1.1. Market Share Analysis By Type I, 2019 vs.2028
4.1.2. Attractive Investment Proposition By Type I, 2020
4.2. Global Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
5. Global Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
5.1. Overview
5.1.1. Market Share Analysis By Application I, 2019 vs.2028
5.1.2. Attractive Investment Proposition By Application I, 2020
5.2. Global Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
6. Global Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
6.1. Overview
6.1.1. Market Share Analysis By End-use, 2019 vs.2028
6.1.2. Attractive Investment Proposition By End-use, 2020
6.2. Global Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7. Global Cardiovascular Drugs Market Size (US$), By Geography, 2018 – 2028
7.1. Overview
7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
7.1.2. Attractive Investment Proposition by Geography, 2020
7.2. North America Cardiovascular Drugs Market Analysis, 2018 – 2028
7.2.1. North America Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.2. North America Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.2.3. North America Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.2.4. North America Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.3. Europe Cardiovascular Drugs Market Analysis, 2018 – 2028
7.3.1. Europe Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.3.1.1. U.K.
7.3.1.2. Germany
7.3.1.3. France
7.3.1.4. Rest of Europe
7.3.2. Europe Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.3.3. Europe Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.3.4. Europe Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.4. Asia Pacific Cardiovascular Drugs Market Analysis , 2018 – 2028
7.4.1. Asia Pacific Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.4.1.1. China
7.4.1.2. Japan
7.4.1.3. India
7.4.1.4. Rest of Asia Pacific
7.4.2. Asia Pacific Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.4.3. Asia Pacific Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.4.4. Asia Pacific Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.5. Latin America Cardiovascular Drugs Market Analysis, 2018 – 2028
7.5.1. Latin America Cardiovascular Drugs Market Size (US$), By Country, 2018 – 2028
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.5.3. Latin America Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.5.4. Latin America Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
7.6. Middle East & Africa (MEA) Cardiovascular Drugs Market Analysis, 2018 – 2028
7.6.1. MEA Cardiovascular Drugs Market Size (US$), By Region, 2018 – 2028
7.6.1.1. GCC Countries
7.6.1.2. South Africa
7.6.1.3. Rest of MEA
7.6.2. MEA Cardiovascular Drugs Market Size (US$), By Type I, 2018 – 2028
7.6.3. MEA Cardiovascular Drugs Market Size (US$), By Application I, 2018 – 2028
7.6.4. MEA Cardiovascular Drugs Market Size (US$), By End-use, 2018 – 2028
8. Company Profiles
8.1. Competitive Analysis
8.2. Market Positioning of Key Vendors
8.3. Key Strategies adopted by the Leading Players
8.4. Key Cardiovascular Drugs Providers
8.4.1 Abbott Laboratories
8.4.1.1 Business Description
8.4.1.2 Abbott Laboratories Geographic Operations
8.4.1.3 Abbott Laboratories Financial Information
8.4.1.4 Abbott Laboratories Product Positions/Portfolio
8.4.1.5 Abbott Laboratories Key Developments
8.4.2 Astellas Pharma, Inc.
8.4.2.1 Business Description
8.4.2.2 Astellas Pharma, Inc. Geographic Operations
8.4.2.3 Astellas Pharma, Inc. Financial Information
8.4.2.4 Astellas Pharma, Inc. Product Positions/Portfolio
8.4.2.5 Astellas Pharma, Inc. Key Developments
8.4.3 AstraZeneca plc
8.4.3.1 Business Description
8.4.3.2 AstraZeneca plc Geographic Operations
8.4.3.3 AstraZeneca plc Financial Information
8.4.3.4 AstraZeneca plc Product Positions/Portfolio
8.4.3.5 AstraZeneca plc Key Developments
8.4.4 Amgen Inc
8.4.4.1 Business Description
8.4.4.2 Amgen Inc Geographic Operations
8.4.4.3 Amgen Inc Financial Information
8.4.4.4 Amgen Inc Product Positions/Portfolio
8.4.4.5 Amgen Inc Key Developments
8.4.5 Aurobindo Pharma Ltd
8.4.5.1 Business Description
8.4.5.2 Aurobindo Pharma Ltd Geographic Operations
8.4.5.3 Aurobindo Pharma Ltd Financial Information
8.4.5.4 Aurobindo Pharma Ltd Product Positions/Portfolio
8.4.5.5 Aurobindo Pharma Ltd Key Developments
8.4.6 Bayer AG
8.4.6.1 Business Description
8.4.6.2 Bayer AG Geographic Operations
8.4.6.3 Bayer AG Financial Information
8.4.6.4 Bayer AG Product Positions/Portfolio
8.4.6.5 Bayer AG Key Developments
8.4.7 Baxter International Inc
8.4.7.1 Business Description
8.4.7.2 Baxter International Inc Geographic Operations
8.4.7.3 Baxter International Inc Financial Information
8.4.7.4 Baxter International Inc Product Positions/Portfolio
8.4.7.5 Baxter International Inc Key Developments
8.4.8 Boehringer Ingelheim GmbH
8.4.8.1 Business Description
8.4.8.2 Boehringer Ingelheim GmbH Geographic Operations
8.4.8.3 Boehringer Ingelheim GmbH Financial Information
8.4.8.4 Boehringer Ingelheim GmbH Product Positions/Portfolio
8.4.8.5 Boehringer Ingelheim GmbH Key Developments
8.4.9 Bristol-Myers Squibb Company
8.4.9.1 Business Description
8.4.9.2 Bristol-Myers Squibb Company Geographic Operations
8.4.9.3 Bristol-Myers Squibb Company Financial Information
8.4.9.4 Bristol-Myers Squibb Company Product Positions/Portfolio
8.4.9.5 Bristol-Myers Squibb Company Key Developments
8.4.10 Cipla Ltd
8.4.10.1 Business Description
8.4.10.2 Cipla Ltd Geographic Operations
8.4.10.3 Cipla Ltd Financial Information
8.4.10.4 Cipla Ltd Product Positions/Portfolio
8.4.10.5 Cipla Ltd Key Developments
8.4.11 Daiichi Sankyo Company Limited
8.4.11.1 Business Description
8.4.11.2 Daiichi Sankyo Company Limited Geographic Operations
8.4.11.3 Daiichi Sankyo Company Limited Financial Information
8.4.11.4 Daiichi Sankyo Company Limited Product Positions/Portfolio
8.4.11.5 Daiichi Sankyo Company Limited Key Developments
8.4.12 Eli Lilly and Company
8.4.12.1 Business Description
8.4.12.2 Eli Lilly and Company Geographic Operations
8.4.12.3 Eli Lilly and Company Financial Information
8.4.12.4 Eli Lilly and Company Product Positions/Portfolio
8.4.12.5 Eli Lilly and Company Key Developments
8.4.13 F.Hoffman-La Roche Ltd
8.4.13.1 Business Description
8.4.13.2 F.Hoffman-La Roche Ltd Geographic Operations
8.4.13.3 F.Hoffman-La Roche Ltd Financial Information
8.4.13.4 F.Hoffman-La Roche Ltd Product Positions/Portfolio
8.4.13.5 F.Hoffman-La Roche Ltd Key Developments
8.4.14 Gilead Science, Inc
8.4.14.1 Business Description
8.4.14.2 Gilead Science, Inc Geographic Operations
8.4.14.3 Gilead Science, Inc Financial Information
8.4.14.4 Gilead Science, Inc Product Positions/Portfolio
8.4.14.5 Gilead Science, Inc Key Developments
8.4.15 GlaxoSmithKline plc
8.4.15.1 Business Description
8.4.15.2 GlaxoSmithKline plc Geographic Operations
8.4.15.3 GlaxoSmithKline plc Financial Information
8.4.15.4 GlaxoSmithKline plc Product Positions/Portfolio
8.4.15.5 GlaxoSmithKline plc Key Developments
8.4.16 Johnson & Johnson
8.4.16.1 Business Description
8.4.16.2 Johnson & Johnson Geographic Operations
8.4.16.3 Johnson & Johnson Financial Information
8.4.16.4 Johnson & Johnson Product Positions/Portfolio
8.4.16.5 Johnson & Johnson Key Developments
8.4.17 Lupin Ltd
8.4.17.1 Business Description
8.4.17.2 Lupin Ltd Geographic Operations
8.4.17.3 Lupin Ltd Financial Information
8.4.17.4 Lupin Ltd Product Positions/Portfolio
8.4.17.5 Lupin Ltd Key Developments
8.4.18 Merck & Co Inc
8.4.18.1 Business Description
8.4.18.2 Merck & Co Inc Geographic Operations
8.4.18.3 Merck & Co Inc Financial Information
8.4.18.4 Merck & Co Inc Product Positions/Portfolio
8.4.18.5 Merck & Co Inc Key Developments
8.4.19 Medicure Inc
8.4.19.1 Business Description
8.4.19.2 Medicure Inc Geographic Operations
8.4.19.3 Medicure Inc Financial Information
8.4.19.4 Medicure Inc Product Positions/Portfolio
8.4.19.5 Medicure Inc Key Developments
8.4.20 Novartis AG
8.4.20.1 Business Description
8.4.20.2 Novartis AG Geographic Operations
8.4.20.3 Novartis AG Financial Information
8.4.20.4 Novartis AG Product Positions/Portfolio
8.4.20.5 Novartis AG Key Developments
8.4.21 Otsuka Pharmaceutical
8.4.21.1 Business Description
8.4.21.2 Otsuka Pharmaceutical Geographic Operations
8.4.21.3 Otsuka Pharmaceutical Financial Information
8.4.21.4 Otsuka Pharmaceutical Product Positions/Portfolio
8.4.21.5 Otsuka Pharmaceutical Key Developments
8.4.22 Pfizer Inc
8.4.22.1 Business Description
8.4.22.2 Pfizer Inc Geographic Operations
8.4.22.3 Pfizer Inc Financial Information
8.4.22.4 Pfizer Inc Product Positions/Portfolio
8.4.22.5 Pfizer Inc Key Developments
LIST OF TABLES
TABLE 1 Market Snapshot: Global Cardiovascular Drugs Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 North America Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 5 North America Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 6 North America Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 7 Europe Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 8 Europe Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 9 Europe Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 10 Asia Pacific Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 11 Asia Pacific Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 12 Asia Pacific Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 13 Latin America Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 14 Latin America Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 15 Latin America Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Cardiovascular Drugs Market Revenue, By Type I, 2018 – 2028 (US$ Mn)
TABLE 17 MEA Cardiovascular Drugs Market Revenue, By Application I, 2018 – 2028 (US$ Mn)
TABLE 18 MEA Cardiovascular Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
LIST OF FIGURES
FIG. 1 Global Cardiovascular Drugs: Market Segmentation
FIG. 2 Global Cardiovascular Drugs Market: Research Methodology
FIG. 3 Top-Down and Bottom-up Approach
FIG. 4 Global Cardiovascular Drugs Market, By Type I, 2019 (US$ Mn)
FIG. 5 Global Cardiovascular Drugs Market, By Application I, 2019 (US$ Mn)
FIG. 6 Global Cardiovascular Drugs Market, By End-use, 2019 (US$ Mn)
FIG. 7 Global Cardiovascular Drugs Market, By Geography, 2019 (US$ Mn)
FIG. 8 Global Cardiovascular Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition
FIG. 10 Market Positioning of Key Cardiovascular Drugs Providers, 2019
FIG. 11 Global Cardiovascular Drugs Market Revenue Contribution, By Type I, 2019 & 2028 (Value %)
FIG. 12 Global Cardiovascular Drugs Market Revenue Contribution, By Application I, 2019 & 2028 (Value %)
FIG. 13 Global Cardiovascular Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %)
FIG. 14 North America Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 15 Europe Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 16 Asia Pacific Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 17 Latin America Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Cardiovascular Drugs Market Revenue, 2018 – 2028, (US$ Mn)
Key Takeaways:
1. Market value and estimate of the Cardiovascular Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage
List of Tables
TABLE Market Snapshot: Global Cardiovascular Drugs MarketTABLE Impact Pointers
TABLE Impact Analysis of Drivers and Restraints
TABLE North America Cardiovascular Drugs Market Value, By Segment1, 2018 – 2028
TABLE North America Cardiovascular Drugs Market Value, By Segment2, 2018 – 2028
TABLE North America Cardiovascular Drugs Market Value, By Country, 2018 – 2028
TABLE Europe Cardiovascular Drugs Market Value, By Segment1, 2018 – 2028
TABLE Europe Cardiovascular Drugs Market Value, By Segment2, 2018 – 2028
TABLE Europe Cardiovascular Drugs Market Value, By Country, 2018 – 2028
TABLE Asia Pacific Cardiovascular Drugs Market Value, By Segment1, 2018 – 2028
TABLE Asia Pacific Cardiovascular Drugs Market Value, By Segment2, 2018 – 2028
TABLE Asia Pacific Cardiovascular Drugs Market Value, By Country, 2018 – 2028
TABLE Latin America Cardiovascular Drugs Market Value, By Segment1, 2018 – 2028
TABLE Latin America Cardiovascular Drugs Market Value, By Segment2, 2018 – 2028
TABLE Latin America Cardiovascular Drugs Market Value, By Country, 2018 – 2028
TABLE MEA Cardiovascular Drugs Market Value, By Segment1, 2018 – 2028
TABLE MEA Cardiovascular Drugs Market Value, By Segment2, 2018 – 2028
TABLE MEA Cardiovascular Drugs Market Value, By Country, 2018 – 2028
TABLE Abbott Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Astellas Pharma, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE AstraZeneca plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Amgen Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Aurobindo Pharma Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Bayer AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Baxter International Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Boehringer Ingelheim GmbH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Bristol-Myers Squibb Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Cipla Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Daiichi Sankyo Company Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Eli Lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE F.Hoffman-La Roche Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Gilead Science, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE GlaxoSmithKline plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Johnson & Johnson: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Lupin Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Merck & Co Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Medicure Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Otsuka Pharmaceutical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Pfizer Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
List of Figures
FIG. Global Cardiovascular Drugs Market: Research MethodologyFIG. Top-Down and Bottom Up Approach
FIG. Global Cardiovascular Drugs Market, By Segment1, 2019 (US$ Mn)
FIG. Global Cardiovascular Drugs Market, By Segment2, 2019 (US$ Mn)
FIG. Global Cardiovascular Drugs Market, By Geography, 2019 (US$ Mn)
FIG. Global Cardiovascular Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. Attractive Investment Proposition
FIG. Market Positioning of Key Cardiovascular Drugs Providers, 2016
FIG. Global Cardiovascular Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG. Global Type I Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Type II Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Type III Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Cardiovascular Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG. Global Application I Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Application II Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Application III Market Value, 2018 – 2028, (US$ Mn)
FIG. U.S. Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Canada Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. UK Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Germany Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. France Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of Europe Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. China Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Japan Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. India Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of Asia Pacific Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Mexico Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Brazil Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of Latin America Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. GCC Countries Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. South Africa Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of MEA Cardiovascular Drugs Market Value, 2018 – 2028, (US$ Mn)